Anteris Technologies Showcases Year-Long Results for DurAVR® THV
MINNEAPOLIS and BRISBANE, Australia – Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), known for its commitment to advancing heart care, has announced that it will present one-year clinical outcomes associated with the innovative DurAVR® Transcatheter Heart Valve (THV). Renowned cardiologist Rishi Puri, MD PhD, will share these significant findings at the prestigious TCT® 2025, the 37th Annual Transcatheter Cardiovascular Therapeutics Conference.
Significant Presentation at a Key Medical Conference
The oral presentation is set for an exciting Monday session within the Innovation Theater, showcasing pioneering concepts in TAVR technology. Dr. Puri will delve into the intriguing results entitled, "The DurAVR® Biomimetic TAVR System in Patients with Small Aortic Annuli: One-Year Clinical and Hemodynamic Outcomes.”
This session promises to reveal important data focusing on clinical outcomes for patients suffering from symptomatic severe aortic stenosis, particularly those with smaller aortic annuli measurements. The anticipation around DurAVR®'s performance reflects its innovative design aimed at redefining treatment options for these patients.
Clinical Outcomes and Future Trials
The encouraging results already observed in over 100 patients implanted with the DurAVR® THV will be rigorously evaluated in the forthcoming global pivotal trial known as the “PARADIGM Trial.” This prospective randomized controlled trial aims to compare the safety and effectiveness of DurAVR® THV to existing transcatheter aortic valve replacements (TAVRs) for severe aortic stenosis treatment.
The PARADIGM Trial reflects Anteris's commitment to advancing heart health technology and will significantly contribute to understanding the merits of the DurAVR® system in a broader clinical context.
About Anteris Technologies
Anteris Technologies Global Corp. stands out as a leader in the structural heart technology space, dedicated to developing innovative medical devices. Established in Australia, with operational bases extending to Minneapolis, USA, Anteris thrives on a science-driven approach. Their talented team of specialists works tirelessly to deliver groundbreaking solutions for patients suffering from structural heart diseases.
The company’s flagship product, the DurAVR® Transcatheter Heart Valve, has been crafted in collaboration with leading interventional cardiologists and cardiac surgeons. It targets the urgent need for effective treatments for aortic stenosis, a significant condition altering proper heart function due to the narrowing of the aortic valve. This balloon-expandable valve is the industry’s first biomimetic alternative, expertly shaped to emulate the functionality of a healthy aortic valve, striving to restore natural blood flow.
The Technology Behind DurAVR® THV
Distinguished by its single-piece molded ADAPT® tissue, the DurAVR® THV ensures longevity and efficacy. This FDA-cleared tissue technology has demonstrated clinical success for over a decade and has been utilized in more than 55,000 patient cases worldwide. The DurAVR® system integrates the uniquely designed valve with the efficient balloon-expandable ComASUR® Delivery System, ensuring optimal delivery and functionality during surgical applications.
The innovation represented by the DurAVR® THV underlines Anteris Technologies' leadership in the evolving field of cardiac solutions, positioning the company at the forefront of efforts aimed at restoring heart health.
Frequently Asked Questions
What is the DurAVR® Transcatheter Heart Valve?
The DurAVR® THV is an innovative medical device designed to treat aortic stenosis by mimicking the natural function of a healthy aortic valve.
What were the results of the one-year clinical outcomes?
The outcomes have shown encouraging results following the implantation of the DurAVR® THV in over 100 patients, emphasizing its potential efficacy.
What is the PARADIGM Trial?
The PARADIGM Trial is a pivotal study aimed at evaluating the safety and effectiveness of the DurAVR® THV in comparison to existing TAVR products.
Who presented these clinical outcomes?
Dr. Rishi Puri, an esteemed cardiologist, will present the results at the TCT® 2025 conference.
How does DurAVR® THV differ from traditional TAVRs?
DurAVR® is the first biomimetic valve designed to replicate a healthy aortic valve's performance, featuring advanced tissue technology for improved outcomes.
